Emerald Advisers, LLC Akero Therapeutics, Inc. Transaction History
Emerald Advisers, LLC
- $2.01 Billion
- Q1 2025
A detailed history of Emerald Advisers, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Emerald Advisers, LLC holds 294,402 shares of AKRO stock, worth $13.4 Million. This represents 0.59% of its overall portfolio holdings.
Number of Shares
294,402
Previous 520,114
43.4%
Holding current value
$13.4 Million
Previous $14.5 Million
17.64%
% of portfolio
0.59%
Previous 0.61%
Shares
6 transactions
Others Institutions Holding AKRO
# of Institutions
214Shares Held
67.4MCall Options Held
321KPut Options Held
558K-
Rtw Investments, LP New York, NY6.86MShares$313 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$275 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$255 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$239 Million5.21% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.32MShares$197 Million0.01% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.12B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...